Predicta Biosciences

Predicta Biosciences is a precision oncology company focused on transforming the patient journey through innovative diagnostic tools. They utilize cutting-edge multiomics and liquid biopsies to develop personalized treatment options for patients. Their technology captures multi-omics and immune system data to create a unique clinical database, which is constantly growing to improve treatment across existing and new therapies. Predicta's mission is to empower clinicians with the tools and knowledge they need to make informed decisions and provide the best possible care.

Predicta's platform uses AI to identify novel drug targets and immune signatures, aiming to one day cure the patients they diagnose. Their diagnostic products eliminate the need for painful bone marrow biopsies by using small blood-based samples, enabling easy diagnosis and monitoring throughout the patient journey. The company's patient-centric culture drives them to create products that meet the needs of patients and empower them with resources and information about their unique molecular data, treatment options, and monitoring recommendations.

Predicta Biosciences is a precision oncology company focused on revolutionizing cancer diagnosis and treatment through innovative blood-based diagnostics. Their mission is to develop personalized treatment options for patients by utilizing cutting-edge multi-omics technology and AI. They aim to remove the need for painful and invasive procedures like bone-marrow biopsies, enabling easier diagnosis and monitoring throughout a patient's journey. Predicta also aims to empower clinicians with the knowledge and tools needed to make informed decisions about treatment, and to provide patients with resources and information about their unique molecular data, treatment options, and monitoring recommendations.

Predicta Biosciences promotes a patient-centric company culture, driven by a commitment to improving healthcare through innovative diagnostics. This translates to a focus on collaboration, innovation, and a strong belief in empowering both clinicians and patients with the knowledge and tools to make informed decisions about treatment and monitoring. The company is comprised of world-class leaders in oncology diagnostics and therapeutics, fostering a collaborative environment where expertise and shared goals are valued.

Predicta Biosciences emphasizes a patient-centric culture, but the company website doesn't explicitly mention its approach to diversity, equity, and inclusion. However, its leadership team features individuals from diverse backgrounds, including researchers, clinicians, and professionals with expertise in healthcare, technology, and finance. This suggests a commitment to inclusivity within the company, though further information is needed to fully understand their approach to DEI.